S Hall1, P Murchie. 1. Centre of Academic Primary Care, Division of Applied Health Science, University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen, AB25 2ZD, UK.
Abstract
PURPOSE: People with melanoma traditionally attend cancer centre-based follow-up. Most recurrences and new primary melanomas are, however, detected by patients between hospital visits. Despite this, total skin self-examination (TSSE) practices are suboptimal. Digital technologies could be used to support TSSE. The attitudes of potential users are unknown; this study aims to explore the attitudes of people with melanoma towards using digital technologies and the effect of personal characteristics on their attitudes. METHODS: Twenty-one hospital joint melanoma clinic patients aged 37-83 were purposively recruited. Semi-structured interviews were conducted to explore patients' views on the use of digital technology during follow-up and identify barriers or facilitators. Interviews were transcribed verbatim and subject to framework analysis. RESULTS: Participants had a wide range of IT skills. All used a mobile phone, most had heard of telemedicine and several had used Skype. Participants felt that with thought, tailoring and training, technology could enable self-monitoring as part of melanoma follow-up. Technological benefits included having a co-ordinating nurse specialist, contactable electronically, and having a personalised skin map and tailored information about melanoma. Participants cautioned that technological developments must take account of personal needs and characteristics. Few had security concerns. CONCLUSIONS: People are not currently equipped to undertake self-monitoring as part of their melanoma follow-up, but many would be keen to employ technology to support this. A range of technologies could be utilised with potential benefits. Technologies should be carefully designed and individually tailored, considering age, familiarity with technology, place of residence and time since diagnosis.
PURPOSE:People with melanoma traditionally attend cancer centre-based follow-up. Most recurrences and new primary melanomas are, however, detected by patients between hospital visits. Despite this, total skin self-examination (TSSE) practices are suboptimal. Digital technologies could be used to support TSSE. The attitudes of potential users are unknown; this study aims to explore the attitudes of people with melanoma towards using digital technologies and the effect of personal characteristics on their attitudes. METHODS: Twenty-one hospital joint melanoma clinic patients aged 37-83 were purposively recruited. Semi-structured interviews were conducted to explore patients' views on the use of digital technology during follow-up and identify barriers or facilitators. Interviews were transcribed verbatim and subject to framework analysis. RESULTS:Participants had a wide range of IT skills. All used a mobile phone, most had heard of telemedicine and several had used Skype. Participants felt that with thought, tailoring and training, technology could enable self-monitoring as part of melanoma follow-up. Technological benefits included having a co-ordinating nurse specialist, contactable electronically, and having a personalised skin map and tailored information about melanoma. Participants cautioned that technological developments must take account of personal needs and characteristics. Few had security concerns. CONCLUSIONS:People are not currently equipped to undertake self-monitoring as part of their melanoma follow-up, but many would be keen to employ technology to support this. A range of technologies could be utilised with potential benefits. Technologies should be carefully designed and individually tailored, considering age, familiarity with technology, place of residence and time since diagnosis.
Authors: M Janda; P D Baade; P H Youl; J F Aitken; D C Whiteman; L Gordon; R E Neale Journal: Contemp Clin Trials Date: 2009-11-11 Impact factor: 2.226
Authors: Susan A Oliveria; Stephen W Dusza; Deborah L Phelan; Jamie S Ostroff; Marianne Berwick; Allan C Halpern Journal: Am J Prev Med Date: 2004-02 Impact factor: 5.043
Authors: P Murchie; J Masthoff; F M Walter; K Rahman; J L Allan; N Burrows; C Proby; A J Lee; M Johnston; A Durrani; I Depasquale; B Brant; A Neilson; F Meredith; S Treweek; S Hall; A McDonald Journal: Trials Date: 2019-06-03 Impact factor: 2.279
Authors: Fiona M Walter; Merel M Pannebakker; Matthew E Barclay; Katie Mills; Catherine L Saunders; Peter Murchie; Pippa Corrie; Per Hall; Nigel Burrows; Jon D Emery Journal: JAMA Netw Open Date: 2020-02-05
Authors: Peter Murchie; Julia L Allan; William Brant; Matthew Dennis; Susan Hall; Judith Masthoff; Fiona M Walter; Marie Johnston Journal: BMJ Open Date: 2015-08-06 Impact factor: 2.692